TickerFiles

BioXcel Therapeutics, Inc. 10-Q filing

Filed 2025-11-12 · Report date 2025-09-30 · 2025

View Original SEC Filing

Filing metadata

Accession number
0001104659-25-109880
Form type
10-Q
CIK
0001720893
Primary document
https://www.sec.gov/Archives/edgar/data/1720893/000110465925109880/btai-20250930x10q.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for BioXcel Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$386,000--
Cost Of Revenue$132,000--
Operating Income$-40.2M--
Net Income$-57.4M--
Eps Basic-6.38--
Eps Diluted-6.38--
Cash And Equivalents$36.2M--
Total Assets$44.8M--
Total Liabilities$133.7M--
Shareholders Equity$-88.9M--
Operating Cash Flow$-43.4M--
Capital Expenditures$0--